In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Special Issue: Targeting the Lysosome

Edited by

Annals of the New York Academy of Sciences editorial staff

Special Issue: Targeting the Lysosome

Published: May 2016

Volume 1371

Published since 1824, Annals of the New York Academy of Sciences is the Academy’s premier scientific publication.

Learn More

The lysosome is the main catabolic hub of the cell. Owing to its role in fundamental processes such as cellular catabolic reactions, membrane repair, and cell death, the lysosome has a profound influence on cellular metabolism and human health. Indeed, inefficient or impaired lysosomal function has been implicated in the pathogenesis of several degenerative diseases affecting various organs and tissues. This special issue presents five review articles stemming from the conference \"Drugs Targeting the Lysosome,\" sponsored by the New York Academy of Sciences and Beyond Batten Disease Foundation in November 2014. The articles discuss recent discoveries in lysosome biology and the therapeutic potential of drugs targeting the lysosome in various diseases. The specific topics covered include the potential of TFEB as a therapeutic target for the treatment of lysosomal storage diseases (LSDs); LSD-relevant cellular and animal models with high clinical predictability; the contributions of lysosomal membrane permeabilization to the pathogenic features of LSDs and other neurodegenerative conditions; the therapeutic potential of drugs targeting the lysosome in cancer and the role of lysosomes in cancer drug resistance; and current understanding of vision loss in juvenile neuronal ceroid lipofuscinosis.